Eye Health News and Research

Latest Eye Health News and Research

NanoViricides files financial year end annual report with SEC

NanoViricides, Inc. reports that it has filed its financial year end annual report (Form 10K) with the Securities and Exchange Commission (SEC) yesterday in a timely manner.

14 Oct 2010

TruStaff fingerprint biometric log-in provides quick access to Medflow EHR

BIO-key International, Inc. a leader in finger-based biometric identification solutions for the healthcare industry, and Medflow Incorporated, the market leader in the development of electronic health records software solely dedicated to eye care physicians, announced the release of TruStaff fingerprint biometric log-in for securing access to Medflow Electronic Health Records (EHR).

14 Oct 2010

Childrens Hospital Los Angeles receives $1M NCI grant for eye port clinical trial to treat retinoblastoma in children

The Vision Center at Childrens Hospital Los Angeles has been awarded a $1 million grant from the National Cancer Institute (NCI) to conduct a clinical trial on a new drug delivery system to treat young children diagnosed with retinoblastoma. The device is designed to deliver chemotherapy through a tiny silicone cup sealed to the outer surface (sclera) of the eye, which can more directly target cancer cells and greatly reduce the side effects caused by current chemotherapy treatments.

14 Oct 2010

OptiMedica to feature Catalys Precision Laser System at Ophthalmology annual meeting

Global ophthalmic device company OptiMedica Corp. has announced that its Catalys Precision Laser System will be featured as part of four clinical presentations at the American Academy of Ophthalmology annual meeting in Chicago on October 16, 17 and 18.

13 Oct 2010

TearLab receives patent for non-invasive tear collection platform

TearLab Corporation today announced that it has been granted U.S. Patent No. 7,810,380, entitled "Systems and methods for collecting tear film and measuring tear film osmolarity." This patent provides the company with broad and blocking intellectual property regarding the measurement of genetic and protein biomarkers within the tear film.

13 Oct 2010

Ocular Therapeutix completes Proof of Principle clinical study with moxifloxacin punctum plug

Ocular Therapeutix, Inc. announced today the completion of a successful Proof of Principle clinical study with their novel sustained drug delivery moxifloxacin punctum plug.

13 Oct 2010

Kuwait Healthy Life Study to examine metabolic health in children

In the face of a dramatic worldwide increase in adolescent obesity and Type 2 diabetes, The Forsyth Institute today announced a research alliance with the Dasman Diabetes Institute of Kuwait to initiate studies that could lay a scientific basis for prevention. This collaboration, called The Kuwait Healthy Life Study, will examine conditions in children that predispose them to obesity and Type 2 diabetes.

13 Oct 2010

Retina Implant announces opening of new manufacturing plant in Tübingen-Reutlingen

Retina Implant AG, a leading developer of subretinal implants for the visually impaired, today announced the opening of a new manufacturing plant to meet anticipated demand for their implants. The company's second human clinical trial will be expanding outside of Germany in early 2011 to European countries including the U.K. and Italy and discussions are underway for potential clinical trials in the United States and Asia. Also looking ahead, the new facility meets manufacturing capabilities required for CE mark approval.

13 Oct 2010

Akonni receives NIJ grant to develop HCID system for SNP identification

Akonni Biosystems, a molecular diagnostics company that develops, manufactures, and plans to market sophisticated genetic testing devices for diagnosing complex infectious and human diseases, today announced receipt of a nearly $500,000 Phase III Grant from the National Institutes of Justice (NIJ).

13 Oct 2010

Alimera to present Iluvien Phase 3 clinical trial data at AAO annual meeting

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that data from its Phase 3 (FAME) clinical trials for Iluvien will be presented this month at the annual meeting of the American Academy of Ophthalmology (AAO) in Chicago.

12 Oct 2010

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

H. Lundbeck A/S (Lundbeck) and Merck, known outside the United States and Canada as MSD, today announced a commercialization agreement for SYCREST (asenapine) sublingual tablets (5 mg, 10 mg). Under the terms of the agreement, Lundbeck will pay an undisclosed fee as well as product supply payments in exchange for exclusive commercial rights to SYCREST in all markets outside the United States, China and Japan. Lundbeck expects to launch SYCREST in the European Union (EU), where it is already approved, at the beginning of 2011.

12 Oct 2010

Study finds no link between AMD treatments and increase in cardiovascular complication

Newer treatments for age-related macular degeneration (AMD)-including an intravitreous (into the eye) injection of a chemotherapy drug and use of a related compound approved for use against the eye disease-do not appear to be associated with an increased risk of cardiovascular complications or death when compared with existing therapies, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

12 Oct 2010

Medicare recipients receiving treatment for retinal condition increases with shifts in procedure

The number of Medicare recipients undergoing treatment for retinal conditions nearly doubled between 1997 and 2007, with significant shifts in the types of procedures most commonly performed, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

12 Oct 2010

IRIDEX introduces new family of Adjustable & Intuitive EndoProbe laser handpieces

IRIDEX Corporation today announced commercial availability of a new family of Adjustable & Intuitive EndoProbe laser handpieces for use with the Company's laser platforms in vitreoretinal surgery.

11 Oct 2010

MingSight acquires worldwide rights from Pfizer to develop new chemical entities for human diseases

MingSight Pharmaceuticals announced today that it has acquired the exclusive worldwide rights from Pfizer to develop, manufacture, and commercialize two preclinical stage new chemical entities for the prevention and treatment of human diseases.

11 Oct 2010

OXiGENE announces ZYBRESTAT Phase 2/3 study results at ESMO Congress

OXiGENE, a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that an ongoing analysis of positive results reported earlier from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented today at the 35th European Society of Medical Oncology (ESMO) Congress in Milan, Italy by Julie Ann Sosa, M.D., F.A.C.S., of Yale University.

11 Oct 2010

First Edition: October 11, 2010

Today's early morning highlights include articles on new options for open season, concerns among retirees about the provisions of the federal health law and the latest campaign arguments over that new overhaul.

11 Oct 2010

Senate leaders eye temporary, one-month 'doc fix' for Medicare reimbursement

Congress Daily: "Senate leaders are eyeing a temporary, one-month patch for a looming Medicare physician pay cut, hoping to buy time to work out a longer-term fix despite pushing deadlines for a number of other provider reimbursement issues.

11 Oct 2010

Abbott to withdraw Meridia medicine from the U.S. market

Abbott will voluntarily withdraw Meridia (sibutramine) from the U.S. market at the request of the U.S. Food and Drug Administration (FDA).

11 Oct 2010

Researchers find new surface adaptation mechanism of biofilm-forming pathogen

Many drug-resistant infections are the result of bacterial biofilms, structured aggregates of bacteria that live on surfaces and that are extremely resistant to environmental stresses. These biofilms impact human health in many ways - cystic fibrosis, for example, is a disease in which patients die from airway bacterial biofilm infections that are invulnerable to even the most potent antibiotics.

11 Oct 2010

Eye Health News and Research

Latest Eye Health News and Research

NanoViricides files financial year end annual report with SEC

TruStaff fingerprint biometric log-in provides quick access to Medflow EHR

Childrens Hospital Los Angeles receives $1M NCI grant for eye port clinical trial to treat retinoblastoma in children

OptiMedica to feature Catalys Precision Laser System at Ophthalmology annual meeting

TearLab receives patent for non-invasive tear collection platform

Ocular Therapeutix completes Proof of Principle clinical study with moxifloxacin punctum plug

Kuwait Healthy Life Study to examine metabolic health in children

Retina Implant announces opening of new manufacturing plant in Tübingen-Reutlingen

Akonni receives NIJ grant to develop HCID system for SNP identification

Alimera to present Iluvien Phase 3 clinical trial data at AAO annual meeting

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

Study finds no link between AMD treatments and increase in cardiovascular complication

Medicare recipients receiving treatment for retinal condition increases with shifts in procedure

IRIDEX introduces new family of Adjustable & Intuitive EndoProbe laser handpieces

MingSight acquires worldwide rights from Pfizer to develop new chemical entities for human diseases

OXiGENE announces ZYBRESTAT Phase 2/3 study results at ESMO Congress

First Edition: October 11, 2010

Senate leaders eye temporary, one-month 'doc fix' for Medicare reimbursement

Abbott to withdraw Meridia medicine from the U.S. market

Researchers find new surface adaptation mechanism of biofilm-forming pathogen

Genetics & Genomics - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Eye Health News and Research

Latest Eye Health News and Research

Genetics & Genomics - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in